Drugs that block RAS, the growth switch stuck on in many cancers, by an indirect route. The drug first attaches to cyclophilin A, a common protein inside cells, and the pair then clamps onto RAS while it is switched on, so RAS can no longer pass its signal along. Daraxonrasib, approved in the United States in 2026 for pancreatic cancer, works this way; others are in trials.
The first KRAS drugs, sotorasib and adagrasib, bind the inactive state of one mutant, G12C. The active, GTP-bound state of RAS has no pocket for a conventional small molecule. Tri-complex inhibitors reach it with help from a second protein: Schulze and colleagues (Science 2023) designed a natural-product-inspired molecule that remodels the surface of cyclophilin A to create a new interface with high affinity and selectivity for active KRAS G12C, and the three-part complex of cyclophilin A, drug and KRAS shut down oncogenic signalling and regressed tumours in several human cancer models.
The same approach has given three kinds of drug, all from Revolution Medicines. Multi-selective, non-covalent inhibitors bind the active state of mutant and wild-type KRAS, NRAS and HRAS: the tool compound RMC-7977 (Holderfield, Nature 2024) and daraxonrasib, RMC-6236 (Jiang, Cancer Discovery 2024; Cregg, J Med Chem 2025), an orally available macrocycle that sits in a composite pocket formed by cyclophilin A and the switch I and switch II regions of RAS. Elironrasib (RMC-6291) is a covalent inhibitor selective for active KRAS G12C. Zoldonrasib (RMC-9805) is covalent and selective for G12D, where the cyclophilin A interface speeds the reaction between the mutant aspartate and a warhead of very low intrinsic reactivity (Weller, Science 2025).
Daraxonrasib is the member with a randomised trial and an approval: in RASolute 302 it lengthened median survival in previously treated metastatic pancreatic cancer to 13.2 months against 6.7 with chemotherapy, and the FDA approved it on 26 August 2026. Its label describes the mechanism in the same terms: binding to cyclophilin A gives a binary complex that binds active RAS, and the tri-complex blocks interactions with downstream effectors and promotes GTP hydrolysis. Zoldonrasib and elironrasib are in clinical trials and have no approval.
The inhibitor binds cyclophilin A; the resulting binary complex binds the active, GTP-bound state of RAS, and the three-part complex blocks RAS from engaging its downstream effectors.
The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.
One of the most cited trial reports Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
The mechanism that let one drug address G12D, G12V and G12R together, which is why the RASolute 302 trial could enrol unselected pancreatic cancer and nearly double survival.
Query for this technology: (TITLE:"RAS ON tri-complex inhibitors" OR ABSTRACT:"RAS ON tri-complex inhibitors" OR TITLE:"Tri-complex inhibitors" OR ABSTRACT:"Tri-complex inhibitors" OR TITLE:"Tricomplex inhibitors" OR ABSTRACT:"Tricomplex inhibitors" OR TITLE:"RAS ON inhibitors" OR ABSTRACT:"RAS ON inhibitors") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RAS(ON) tri-complex inhibitors, not a curated reading list.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors.
Shares Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy, Elironrasib, Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer, Zoldonrasib.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors.
Shares Zoldonrasib, Revolution Medicines, KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib.
Shares Elironrasib, Zoldonrasib, Revolution Medicines, Daraxonrasib.
Shares Revolution Medicines, KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib, KRAS & RAS inhibitors.
Shares RASolute 302, KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, KRAS.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/